GSK 1437173A

Drug Profile

GSK 1437173A

Alternative Names: GSK1437173A; Herpes zoster vaccine candidate (Hz/su) - GlaxoSmithKline; QS-21 containing herpes zoster vaccine - GlaxoSmithKline/Agenus; Shingrix; Varicella zoster vaccine - GlaxoSmithKline; Varicella zoster virus vaccine - GlaxoSmithKline; VZV vaccine - GlaxoSmithKline/Agenus

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Japan Vaccine
  • Class Subunit vaccines; Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Herpes zoster

Most Recent Events

  • 14 Sep 2017 The FDA's Vaccines and Related Biological Products Advisory Committee recommends approval of GSK 1437173A for Herpes zoster (In adults, In the elderly, Prevention) in USA
  • 13 Sep 2017 Preregistration for Herpes zoster (Prevention) in Australia (IM) before September 2017
  • 01 Aug 2017 GlaxoSmithKline completes a phase III trial for Herpes Zoster in USA (NCT02581410)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top